Comparison of hemodynamic response during anesthesia induction using Dexmedetomidine and Midazolam in hypertensive patients undergoing orthopedic surgery

Abstract

The aim of this study was to compare the effect of dexmedetomidine and midazolam in controlling hemodynamic changes by induction of anesthesia in hypertensive patients candidates for orthopedic surgery. Materials and methods: In this double-blind randomized comparative clinical trial, hypertension patients referred to the operating rooms of Shohada Hospital of Tabriz University of Medical Sciences between December 2020 and June 2021 were enrolled. After the approval of the Research Council of the Medical School of Tabriz University of Medical Sciences and the Ethics Committee of the Faculty of Medical of Tabriz University, a total of 130 patients were participated in this study. The aim of this study was to compare the rate of hemodynamic changes before, during and after induction of anesthesia. Patients were divided into two groups: D hypertensive patients receiving Dexmedetomidine 0.1 µg / kg and M hypertensive patients receiving Midazolam 0.03 mg / ml. Results: The mean age of participants in this study was 64.39 ± 11.98. A total of 70 men (including 37 in the Dexmedetomidine group and 33 in the Midazolam group) and 60 women (including 28 in the dexmedetomidine group and 32 in the midazolam group) participated in the study. The results of this study showed that 1, 3, 5 and 10 minutes after endotracheal intubation, patients treated with dexmedetomidine had lower heart rates than midazolam recipients (p <0.05). Except for the difference in systolic blood pressure 3 minutes after endotracheal intubation, which was lower in the midazolam group (p <0.05), no significant difference was observed in systolic, diastolic and mean blood pressures (p> 0.05). Also, this study could not find a significant difference in patients' SpO2 between the two groups (p> 0.05). 1 minute after endotracheal intubation, drop of systolic and diastolic blood pressure was significantly higher in the midazolam group comparing with the dexmedetomidine group (p <0.05).